CLINICAL_TRIALS
trial_result
· 2022-12-21
Clinical Trial Update: An Extension of the TG1101-RMS201 Trial [Phase 2]
Summary
An extension study of TG1101-RMS201 in relapsing-remitting multiple sclerosis has completed Phase 2.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: TG Therapeutics, Inc. | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED